

# Low-dimensional clustering detects incipient dominant influenza strain clusters

Jiankui He<sup>1</sup> and Michael W. Deem<sup>1,2</sup>

<sup>1</sup>Department of Physics & Astronomy, Rice University, Houston, Texas, USA

<sup>2</sup>Department of Bioengineering, Rice University, Houston, Texas, USA

\* E-mail: Corresponding mwdeem@rice.edu

## Abstract

Influenza has been circulating in the human population and has caused three pandemics in the last century (1918 H1N1, 1957 H2N2, 1968 H3N2). The 2009 A(H1N1) was classified by the World Health Organization (WHO) as the fourth pandemic. Influenza has a high evolution rate, which makes vaccine design challenging. We here consider an approach for early detection of new dominant strains. By clustering the 2009 A(H1N1) sequence data, we found two main clusters. We then define a metric to detect the emergence of dominant strains. We show on historical H3N2 data that this method is able to identify a cluster around an incipient dominant strain before it becomes dominant. For example, for H3N2 as of March 30, 2009, the method detects the cluster for the new A/British Columbia/RV1222/2009 strain. This strain detection tool would appear to be useful for annual influenza vaccine selection.

*Keywords:* clustering/H1N1/H3N2/influenza

## Introduction

The recent outbreak of 2009 A(H1N1) caused immediate international attention [1–4]. This new 2009 A(H1N1) virus contains a combination of gene segments from swine and human influenza viruses [2, 3]. Confirmed infections reached 270,000 globally as of September 2009 [5]. The novel 2009 A(H1N1) strain was defined as a pandemic strain by the World Health Organization (WHO) in 2009 [6], and was the epidemic strain in the 2009 Northern winter.

Influenza viruses are hyper-mutating viruses. It has been estimated that the nucleotide mutation rate per genome per replication is approximately 0.76 [7]. Influenza viruses escape the human immune system by continual antigenic drift and shift [8–13]. The quasispecies nature of influenza viruses makes the strain structure complex [14]. Usually, there is one or a few dominant influenza strains circulating in the population for each flu season. The flu vaccine is most effective when it matches this dominant circulating strain [15, 16]. The degree to which immunity induced by a vaccine protects against a different viral strain is determined by the antigenic distance between the vaccine and the virus. Due to evolution of the antigenic regions of the influenza virus, the composition of the flu vaccine is typically modified annually [17]. However, since the influenza strains used in the flu vaccine are decided 6 months before the flu season, a mismatch between the vaccine strain and dominant circulating strain may occur if the virus evolves significantly. Such a situation arose for the H3N2 virus in the 2009–2010 flu season, when A/British Columbia/RV1222/2009 emerged in the early spring [18, 19]. Accurate early prediction of the dominant circulating strain is an essential and important task in influenza research.

Understanding the evolution of influenza viruses has benefited from phylogenetic reconstructions of the hemagglutinin protein evolution [11, 20]. In an alternative approach, Lapedes and Farber [21], followed by Smith *et al.* [22], applied a technique called multidimensional scaling to study antigenic evolution of influenza. Plotkin *et al.* clustered hemagglutinin protein sequences using the single-linkage clustering algorithm and found that influenza viruses group into clusters [23].

Here, we present a low-dimensional clustering method that can detect the cluster containing an incipient dominant strain for an upcoming flu season before the strain becomes dominant. The method builds upon the dimensional projection technique used by Lapedes and Farber [21] and Smith *et al.* [22]

to characterize hemagglutination inhibition data. In this paper, we first study the evolution of 2009 A(H1N1) by an evolutionary path map which leads to a suggestion for the H1N1 vaccine strain. Then, we introduce the low-dimensional protein sequence clustering method. We propose an influenza vaccine selection procedure based on this sequence clustering. The procedure is demonstrated and tested in detail using historical data. We show the performance of the method to predict the dominant H3N2 strain in an upcoming flu season using data solely from before the flu season, on data since 1996. We compare the results to those from existing methods since 1996. In the discussion section, we discuss the relationship between the protein sequence clustering method and previous approaches. We discuss the false positive rate, as well as other challenges.

## Results

### Evolutionary path of 2009 A(H1N1) influenza

We first construct the directional evolutionary path for the 2009 A(H1N1) influenza. We use high resolution data in sequence, time, and world spatial coordinate to construct this evolutionary relationship. Since its first detection, the 2009 A(H1N1) virus has been extensively sequenced [2,3]. By May 1, 2009, the number of confirmed cases reported by WHO was 333 [5]. At the same time, the sequenced hemagglutinin protein (HA) available in NCBI Influenza Resources Database were 312 [24]; that is to say most of the confirmed cases at that time were sequenced. At July 1, 2009, the ratio of sequenced HA protein to confirmed cases by WHO was 1039/77201 [5], a number which is still much larger than that for seasonal flu. In addition, the Influenza Resources Database contains the date of collection of each 2009 A(H1N1) virus strain. We reconstruct the evolutionary history of swine flu viruses with the following procedure. If strain B is mutated from strain A, we term strain A “founder” and strain B “F1”. We align the HA proteins of all 2009 A(H1N1) strains. Then, for each strain, we find its founder strain based on the following four criteria: 1, the founder strain should appear earlier than the strain, as judged by collection date; 2, the founder strain should have only one amino acid difference in the HA1 protein relative to the F1 strain; 3, the founder should also have the most similar nucleotide sequence relative to F1; and 4, the founder strain should have a large number of identical copies circulating in human population, as approximated by the number of different strains with identical HA sequences in the Influenza Resources Database. By applying these four criteria to 2009 A(H1N1) influenza, we construct the directional evolutionary path map, as shown in Fig. 1. We can see two clusters: one around A/New York/19/2009 (#28), and another one around A/Texas/05/2009 (#12). Most new strains are from the Northern hemisphere, and strains from the Southern hemisphere are mainly located at the edge of the map, such as strain #96, #120, and #126. Geographically, we see many founder to F1 links are from US and Mexico to other countries, but we rarely see founder to F1 links that are from other countries to US and Mexico, or from other countries to other countries except US and Mexico (see Materials and Methods). We also found that strains with more F1 in Fig. 1 are more frequently seen in the human population. For example, in the Influenza Resources Database, we found 153 strains to be identical with A/New York/19/2009, which has 29 F1 strains, and 120 strains to be identical with A/Texas/05/2009, which has 24 F1 strains. We can see in Fig. 1 that A/Texas/05/2009 is at the very upstream of the map, with downward connections to most of the other strains by direct or two-step links. This result agrees with the US Food and Drug Administration [25] recommendation of A/Texas/05/2009 as a vaccination strain. The alternative vaccine strain A/California/7/2009 (#7) has fewer F1 strains and it is not located at the center of the network.

### Low-dimensional clustering

We use a low-dimensional clustering method to visualize the antigenic distance matrix of the viruses. We use a statistical tool called “multidimensional scaling” [26]. This method was used by Lapedes

and Farber [21] and Smith *et al.* [22] to project ferret hemagglutination inhibition assay data to low dimensions. The influenza viral surface glycoprotein hemagglutinin is a primary target of the protective immune response. Here we project the hemagglutinin protein sequence data, rather than animal model data, to low dimensions. The HA1 protein of influenza with 329 residues can be considered as a 329-dimension space. The multidimensional scaling method is applied to rescale the 329-dimension space to a 2-dimensional space, so that we can plot and visualize it. First, we do a multialignment of the HA1 proteins. Then, the distance between any two proteins is calculated as

$$d_{ij} = \frac{1}{N} \sum_{m=1}^N (1 - \delta_{s_{i,m}, s_{j,m}}) \quad (1)$$

where  $s_{i,m}$  is the amino acid of protein  $i$  at position  $m$ . The term  $\delta_{s_{i,m}, s_{j,m}}$  is 1 if amino acids of protein  $i$  and  $j$  at position  $m$  are the same. Otherwise, it is 0. For the 2009 H1N1 viruses, we consider the entire HA protein, and  $N = 566$ . For H3N2 viruses, we consider only the HA1 protein, and  $N = 329$ , because the entire HA proteins are not completely sequenced in many cases. Thus,  $d_{ij}$  is the number of amino acid differences between HA proteins normalized by length. The multidimensional scaling produces a protein distance map, for example, Fig. 2(b). In this map, each data point represents a flu strain isolate. The Euclidean distance between two points in the map approximates the protein distance in Equation 1 between these two flu strains (see Materials and Methods for details of this distance approximation procedure). Two closely located points imply two strains with similar HA protein sequences.

We apply the low-dimensional clustering method to study 2009 A(H1N1). We plot the protein distance map in Fig. 2(b). Both A/Texas/05/2009 and A/New York/19/2009 are located near the center of the cluster, in good agreement with the observation from Fig. 1 that they are the founder strains for many F1 strains. To detect the clusters in the protein distance map, we use a statistical method known as kernel density estimation [26]. Kernel density estimation is a non-parametric method to estimate the probability density function from which data come. The kernel density figure is produced from the protein distance map, and it shows the density of influenza strains in sequence space. We plot the kernel density as the three dimensional shaded surface. For example, the kernel density surface Fig. 2(a) is produced from Fig. 2(b). The  $x$  and  $y$  axes in Fig. 2(a) are the same as that in Fig. 2(b) and are protein distance coordinates. The  $z$  dimension measures the density of flu strains around point  $(x, y)$ . We use the surface height and the colors to represent  $z$  values, and the color is proportional to surface height. A peak in kernel density Fig. 2(a) indicates a cluster of related flu strains in the protein distance map Fig. 2(b)

There are two significant clusters in the Fig. 2(a), as two peaks are observed. The cluster on the left side contains A/Texas/05/2009. Another cluster on the right side contains A/New York/19/2009. The 2009 A(H1N1) virus has evolved slowly to date. The greatest  $p_{\text{epitope}}$  antigenic distance (definition in the Materials and Methods) between A/Texas/05/2009 and all sequenced strains is measured to be  $< 0.08$ . Values of  $p_{\text{epitope}}$  less than 0.45 for H1N1 indicate positive expected vaccine efficacy [27], and so a vaccine is expected to be efficacious. All of the amino acids in all five epitopes of a strain of A/Texas/05/2009 and a strain of A/New York/19/2009 are the same. Multidimensional scaling predicts that A/Texas/05/2009 will be the dominant strain in the 2009–2010 season, and that A/Texas/05/2009 is a suitable strain for vaccination. Our focus is on the expected vaccine effectiveness, as it can be judged from antisera HI assay or sequence data alone. We do not consider other aspects such as growth in hen’s eggs or other manufacturing constraints. Laboratory growth and passage data are needed to address these aspects.

## H3N2 virus evolution for 40 years

We construct the protein distance map to determine the evolution of influenza A(H3N2) virus from 1969 to 2007. Sequences of HA1 proteins were downloaded from the Influenza Virus Resources database [24]. We use the multidimensional clustering method [21] to generate the protein distance map and corresponding kernel density estimation in Fig. 3. Smith *et al.* [22] produced a similar graph using ferret antisera HI

assay data. The figure presented here has a higher resolution, and more clusters are observed, because protein sequences data are more abundant and accurate than antisera HI assay data. The evolution of influenza tends to group strain into clusters. In Fig. 3, we identified 14 major clusters by setting a cutoff value of kernel density. We marked each cluster by the first vaccine strain in the cluster. The average duration time for a cluster is 2.7 years, which is also the approximate duration of a vaccine. There are apparent gaps between clusters. The antigenic distance between two strains in two separate clusters is larger than the distances within the same cluster. The influenza virus evolves within one cluster before jumping from one cluster to another cluster. This dynamics occurs because small antigenic drift by one or a few sequential mutations does not lead the virus to completely escape from cross immunity induced by vaccine protection or prior exposure.

For vaccine design, when the viruses evolve as a quasispecies in the same cluster, the vaccine that is targeted to the cluster provides protection. This protection decreases with antigenic distance. When the viruses jump to a new cluster by antigenic drift or shift, one would want to update the vaccine to provide protection against strains in the new cluster. In Fig. 3(a), the arrows point to the exact position of vaccine strains. It can be seen that the positions of vaccine strains are near the center of clusters. It can be shown mathematically that choosing the consensus strain of a cluster as vaccine strain minimizes the  $p_{\text{epitope}}$  antigenic distance between vaccine strain and cluster strains, and thus maximizes expected vaccine efficacy.

## Influenza vaccine strain selection

We now use the low-dimensional sequence clustering method in an effort to detect a new flu strain before it becomes dominant. A question of interest in the influenza research is whether we can predict which strain will be dominant in the next flu season based on the information we have at present. The WHO gathers together every February to make a recommendation for influenza strains to be used in vaccine for next flu season in the Northern hemisphere. The vaccine is expected to have high efficacy if the chosen strain is dominant in the next flu season. The recommendation is especially challenging to make when the dominant strain in next flu season has not been dominant before February of that year. For example, in mid-March 2009, a new H3N2 strain appeared [18, 19], which infected a significant fraction of the population in the Southern hemisphere.

The current accepted influenza vaccine strain selection procedure is as follows [17]. Isolates samples are collected by WHO GISN and are characterized antigenically using the hemagglutination inhibition(HI) assay. About 10% of samples are also sequenced in HA1 domain of HA gene. Antigenic maps are constructed from the HI assay data using dimensional projection technique. Examination of HI data is not dependent on analysis using dimensional projection, but rather, the primary HI data may carry the most weight. If the vaccine does not match the current circulating strains, the vaccine is updated to contain one representative of the circulating strains. The emerging variant strains are identified. If the antigenically distinct emerging variants are judged to be the dominant strains in the upcoming season, the vaccine is updated to include one representative of emerging variants. The key issue and major difficulty is how to judge whether emerging variants will be the dominant variants in next season. If a fourfold difference in antisera HI titer between the vaccine strain and the emerging strains is observed, the emerging strain is to be determined to be dominant strains in upcoming season, and an updated vaccine is recommended to include the emerging strains [17].

Here, we propose a modified vaccine selection process based on clustering detection. First, we apply the multidimensional scaling to make a protein distance map from HA1 sequences, instead of constructing an antigenic map from HI assay data. Then, we use kernel density estimation to determine the clusters of strains. If the vaccine does not match the current circulating cluster, the vaccine is updated to contain the current circulating strain. If the vaccine matches the current circulating cluster, but an emerging cluster is judged likely to be the major cluster in the upcoming season, the vaccine is updated to contain the consensus strain of the emerging cluster. We judge whether a cluster is an

emerging dominant cluster by two criteria. The first criterion is that this cluster can be detected by kernel density estimation, and is separate from the cluster that contains the current circulating strain or vaccine strain. A cluster that can be detected by kernel density estimation usually contains a central strain that has multiple identical copies and some F1 strains that are closely related to the central strain. An example is the cluster of A/Texas/05/2009(H1N1) in Fig. 1. A/Texas/05/2009(H1N1) is the central strain, which has 120 strains with identical HA protein sequences in the Influenza Virus Resource database [24]. A/Texas/05/2009(H1N1) also has 29 F1 strains with one amino acid different. So, A/Texas/05/2009(H1N1) and the surrounding strains form a cluster as we detected in Fig. 2 by kernel density estimation.

The second criterion is that the current vaccine strain does not match the consensus strain of the cluster and is estimated to provide low protection against strains in the cluster. That is, an immune response stimulated by a vaccine cannot effectively protect against infection by sufficiently distant new strains. The consensus strain is a protein sequence that shows which residues are most abundant in the multialignment at each position. The efficacy of current vaccine to the new cluster can be estimated from ferret antisera HI assay data. However, the antisera data has low resolution and has an imperfect correlation to vaccine effectiveness in humans [16, 28]. Instead, we use  $p_{\text{epitope}}$ , which is calculated as the fraction of mutations in dominant epitope, to estimate vaccine efficacy and which has a more robust correlation to vaccine effectiveness in human than do ferret HI data [16]. When the  $p_{\text{epitope}}$  between the current vaccine strain and consensus strain of the new cluster is larger than 0.19, expected vaccine efficacy decreases to 0 for H3N2 influenza, and the current vaccine cannot be expected to provide protection from new strains. As the examples shown below, our method can detect an incipient dominant strain at its very early stage, and the method appears to require about 10 sequences in the new cluster for detection.

## Demonstration of low-dimensional sequence clustering method.

We demonstrate the method of detecting the A/Fujian/411/2002(H3N2) strain. The A/Panama/2007/1999 had been the vaccination strain for four flu seasons between 2000 and 2004 in the Northern hemisphere. The vaccine strain was replaced by A/Fujian/411/2002(H3N2) in the 2004-2005 flu season, as described in Table 1. The vaccine strain in the 2003-2004 season was A/Panama/2007/1999, while the dominant circulating strain became A/Fujian/411/2002(H3N2). This mismatch resulted in a large decrease in vaccine efficacy in the 2003-2004 flu season [16]. The vaccine efficacy is estimated to be only 12% [29]. We test whether our method can detect A/Fujian/411/2002(H3N2) as an incipient dominant strain before it actually became dominant. We use only virus sequence data before October 1, 2003. We did not use any virus data collected in 2003-2004 season. Therefore, our prediction and results are made without any knowledge from what happened in the 2003-2004 season. We plot the protein distance map of the 2001-2002 flu season in Fig. 4(d). To detect the clusters, we plot the kernel density in Fig. 4(b) for the data in Fig. 4(d). There are two separate significant clusters. The one with the largest kernel density on the left contains the current dominant strain A/Panama/2007/1999 and the widespread A/Moscow/10/1999 strain. The smaller one on the right is a new cluster, which contains A/Fujian/411/2002. Using the data as of September 30, 2002, we seek to determine whether the new cluster on the right in Figs. 4(b) and (d) will be the next dominant strain after A/Panama/2007/1999. We determine whether this cluster fulfills the two criteria above. First, this new cluster can be significantly detected by kernel density estimation. This cluster is separate from the current dominant strain, as we can see in figure. Second, we calculated the average  $p_{\text{epitope}}$  of the new cluster on the right with regard to A/Moscow/10/1999, A/Panama/2007/1999 and A/Fujian/411/2002 to be 0.214, 0.1214, and 0.083, respectively. This means the current vaccine contains A/Moscow/10/1999 is expected to provide little protection against viruses in the new cluster. This result makes the new cluster fulfill the second criterion. Thus, we predict based on the data as of September 30, 2002, that the cluster on the right in Fig. 4(d) will be the next dominant cluster. This prediction was made on data collected one year earlier than when the A/Fujian/411/2002 became dominant in the 2003-2004 season. To further support our prediction, in Fig. 4(c), we plot the

protein distance map from October 1, 2002, to February 1, 2003, right before the WHO selected the vaccine strain for 2003-2004 season. To detect the clusters, we plot the kernel in Fig. 4(a) for the data in Fig. 4(c). There are two separate major clusters observed in the kernel density estimation in Fig. 4(a). The left cluster has the current dominant strain of A/Panama/2007/1999 and also A/Moscow/10/1999. The right cluster has the A/Fujian/411/2002. We calculated the average  $p_{\text{epitope}}$  of the right new cluster with regards to A/Moscow/10/1999, A/Panama/2007/1999, and A/Fujian/411/2002 to be 0.2725, 0.1811, and 0.0367 respectively. This result further supports the prediction that the new cluster will become dominant, and A/Fujian/411/2002, which is the most frequent strain in the new cluster, will be or is very close to the next dominant strain. This suggestion precedes the vaccine component switch by 1-2 years, as shown in Table 1.

### Prediction for H3N2 influenza in 2009–2010.

By applying our method to the 2008-2009 flu season, we predict that the dominant H3N2 strain in the 2009–2010 flu season may switch. Based on the flu activity in the 2008-2009 flu season, the WHO made the recommendation in February 2009 that A/Brisbane/10/2007(H3N2) should be used as the vaccine [30]. However, a new strain evolved just after the recommendation was published. The British Columbia Center for Disease Control detected a new virus strain [18, 19] with 3 mutations in antigenic sites (two in epitope B and one in epitope D). Since this new strain is relatively far from the vaccine strain, with  $p_{\text{epitope}} = 0.095$ , vaccine efficacy is expected to decrease to 20% [1, 16]. However, since the mutations in this new strain “do not fulfill the criteria proposed by Cox as corresponding to meaningful antigenic drift” [18, 31], and this strain still remained the minority of H3N2 viruses in July 2009, health authorities were not certain that this new strain would replace the current dominant strain in 2009–2010 flu season. We use our method to investigate whether this new strain will be the next dominant strain. We construct the protein distance map as shown in Fig. 5(c). We plot the kernel density estimation in Fig. 5(a) for data in Fig. 5(c). By the data up to June 14, 2009, we see two major clusters in Fig. 5(a). The larger one on the right contains the current dominant strain A/Brisbane/10/2007, and the left one is a new cluster which contains A/British Columbia/RV1222/2009. It is apparent that this new cluster is separate from the current dominant cluster. Thus, this cluster fulfills the first criterion. We calculated the average of  $p_{\text{epitope}}$  of strains in the left new cluster with regards to A/Brisbane/10/2007 and A/British Columbia/RV1222/2009 to be 0.103 and 0.042 respectively. The vaccine that contains A/Brisbane/10/2007 has an expected efficacy of 20% to the virus strains in the new cluster. Thus, this new cluster satisfies both two criteria, and so we predict that this cluster which contains A/British Columbia/RV1222/2009 will be the dominant cluster in the 2009–2010 season. The earliest time for us to make this prediction is March 30, 2009. In Fig. 5(d) and (b), we already see this new cluster on the left side of figure, though since there are only about 10 sequences in the new cluster, the kernel density of this new cluster is smaller than that in the dominant cluster. This strain was mentioned as a concern on 5 May 2009, although by conventional methods the strain was not considered a potentially new dominant strain in July 2009 [18]. With the method of the present paper, this new cluster is suggested earlier using the data as of March 30, 2009.

### Comparison with previous results.

Here we present a historical test of the method. For each flu season in the North Hemisphere from 1996, we use only the H3N2 sequences data until February 1, before WHO published the recommendation for vaccine. We use the low dimensional clustering to made the prediction for the dominant strain. The conventional method as used by WHO is phylogenetic analysis combined with ferret antisera HI assay. In Table 1, we compare the method with the conventional method. In the most recent 14 flu seasons, influenza subtype H3 was dominant in 10. The WHO H3N2 vaccine component matches the circulating strains in 8 seasons. Our predictions match the circulating strains in 9 seasons. In 1997-1998

season, a novel flu strain Sydney/5/97 was found in June 1997. Because no similar strains were collected before February 1, neither of the two methods can predict it. In 2003-2004 season, our method predicts Fujian/441/2002 as the dominant strain, while phylogenetic analysis combined with ferret antisera HI assay did not. For all other 8 seasons dominated by influenza subtype H3, the predictions of both methods matched the dominant circulating strain. The 2009–2010 influenza season was dominated by H1N1. But data from local outbreaks of H3N2 infections [18, 19] showed that the dominant H3N2 strain was A/British Columbia/RV1222/2009, as predicted in Table 1, rather than the vaccine strain A/Brisbane/10/2007. For the 2010-2011 season, we recommend A/British Columbia/RV1222/2009 as a vaccine strain, and the WHO recommended A/Perth/16/2009. These two strains are in the same cluster and antigenically similar with a small  $p_{\text{epitope}} = 0.048$ . Although these two strains are slightly different, the vaccine is expected to be effective.

### Detecting A/Wellington/1/2004 in the 2004 flu season in the Southern hemisphere

The low-dimensional clustering can also be applied to influenza in the Southern hemisphere. As an example, we test our method on the 2004 flu season. The recommended H3N2 vaccine strain by WHO used in the 2004 flu season in the Southern hemisphere was A/Fujian/411/2002. Data from the surveillance network suggested that the circulating dominant flu strain in the 2004 season in Southern hemisphere was A/Fujian/411/2002, and a late surge of A/Wellington/1/2004 was also observed. For example, in Argentina, a study showed that about 50% of infections were closely related to A/Fujian/411/2002 and another 50% were closely related to A/Wellington/1/2004 [32]. In New Zealand, the dominant flu strain was A/Fujian/411/2002 which caused 78% of flu infections [33], and a late season surge of A/Wellington/1/2004 was also reported [34]. Therefore, the vaccine recommended by WHO matches the dominant strain and would be expected to have vaccine efficacy in the 2004 season in Southern hemisphere.

We here use the low-dimensional clustering method to detect the A/Wellington/1/2004 strain, which is not the major dominant strain but caused significant infections in the 2004 flu season. We plot the protein distance and kernel density estimation for the H3N2 viruses in Fig. 6(d) and 6(b). We use the data only as of February 1, 2004, 3 months prior to the 2004 flu Southern hemisphere season, which is usually from May to September. We observed two clusters. The major cluster on the left side of Fig. 6(d) is A/Fujian/411/2002-like, which was the vaccine strain in 2004 season. There is a new cluster in the right side of Fig. 6(d) which contains A/Wellington/1/2004. The  $p_{\text{epitope}}$  of A/Wellington/1/2004 with regards to A/Fujian/411/2002 is 0.118. Therefore, we predict that A/Wellington/1/2004 will infect a large fraction of the population, and the A/Fujian/411/2002 vaccine is expected to provide only partial protection against the A/Wellington/1/2004 virus. However, since the appearance of A/Wellington/1/2004 was just before the the 2004 flu season, it did not have sufficient time to spread out and become the dominant strain in the 2004 flu season. From our observation, it usually takes about 8 months or longer for a new strain to become dominant after its appearance in a new cluster. Therefore, the predominant flu strain in 2004 season is expected to be A/Fujian/411/2002 based on the data as of February 1, 2004. This result agrees with the dominant flu strain in the 2004 flu season.

### Detecting A/California/4/2004 as a future dominant strain

As a further example of applying the low-dimensional clustering method to influenza in Southern hemisphere, we test the method on the 2005 flu season. The recommended H3N2 vaccine strain in the 2005 flu season in the Southern hemisphere was A/Wellington/1/2004. Data from HI assay tests and surveillance suggest that the dominant H3N2 strain in the 2005 season was A/California/7/2004. In HI tests with postinfection ferret sera the majority of influenza A(H3N2) viruses from February 2005 to October 2005 were closely related to A/California/7/2004, as reported by WHO on October 7, 2005 [35]. Surveillance

data from Victoria, Australia, show that 45% of influenza A infections were A/California/7/2004-like (H3), 11% were A/Wellington/1/2004 (H3) and 44% were A/New Caledonia /20/99-like (H1), as collected in the 2005 flu season [36]. Surveillance data from New Zealand also show that the dominant H3N2 strain in the 2005 flu season was A/California/7/2004 [37].

We plot the protein distance for the H3N2 viruses in the 2003-2004 flu season in Fig. 6(c). We only use the data as of September 30, 2004, earlier than the October 2004 date when the WHO published the influenza vaccine recommendation for Southern hemisphere. We plot the kernel density estimation in Fig. 6(a) for the data in Fig. 6(c). There are three major clusters in Fig. 6(a). The one on the left is the current dominant cluster which are mostly A/Fujian/422/2002-like viruses. There is a middle cluster centered on A/Wellington/1/2004. The one on the right contains A/California/7/2004. Both the A/California/7/2004 cluster and the A/Wellington/1/2004 cluster are antigenically novel from A/Fujian/411/2002.

When the protein distance map and kernel estimation as of February 1, 2004, is plotted in Fig. 6(d) and (b), we still see the A/Wellington/1/2004 cluster. With these data, the A/California/7/2004 cluster is no longer observed. Thus, A/California/7/2004 cluster is a newly appearing cluster and we consider it to be the emerging strain. The new cluster which contains A/California/7/2004 is separate from the current dominant cluster. We calculated the average  $p_{\text{epitope}}$  of the new cluster that contains A/California/7/2004 with regard to A/Fujian/411/2002 to be 0.112. This makes the new cluster fulfill both criteria for an incipient dominant strain cluster. So we predict based on the information as of September 30, 2004, that A/California/7/2004 will be the next dominant strain after A/Fujian/411/2002 in Southern hemisphere. We further predict from these data that A/California/7/2004 will be the dominant strain in the following flu season in the Northern hemisphere. These predictions agree with the observed dominant strain in the 2005 flu season.

## Discussion

The evolution of influenza virus is driven by cell receptor distributions, non-specific innate host defense mechanisms, cross immunity [10,11], and other contributions to viral fitness. In this paper, we focused on HA protein evolution under antibody selection pressure. The degree to which the immunity induced by one strain protects against another strain depends on their antigenic distance [16]. Because the human immune response to viral infection is not completely cross protective, natural selection favors amino-acid variants of the HA protein that allow the virus to evade immunity, infect more hosts, and proliferate. Mutant strains surround the dominant strain and group into a cluster rather than evolve in a defined direction [22,23]. After the virus has circulated in population for one or more years, effective vaccines and cross immunity of the population drive the evolution of influenza by mutation and reassortment. This evolution increases the immune-escape component of the fitness of new strains, and eventually causes a new epidemic. These new immune-escape strains will form a new cluster, and the old clusters will die out, thus starting a new cycle. This process of creating of new clusters is what our method detects.

The low dimensional clustering can be used not only in genetic sequences but also on distances calculated from inhibition assays of antibody and antigens, as developed by Lapedes and Farber [21] and Smith *et al.* [22]. The inhibition assay provides an approximation of antigenic distance and is broadly used as a marker for vaccine efficacy. The inhibition assay suffers from low resolution of data, which multidimensional scaling improves, and is less able to predict the vaccine efficacy than the  $p_{\text{epitope}}$  method [16]. The genetic sequences used here are a direct description of the evolution of pathogen and antigenic distance of influenza. To aid vaccine selection, the low dimensional clustering on genetic sequences appears informative.

Challenges may arise in application of the method described here. If two or more new clusters appear in one season, additional information is needed to decide which cluster should be chosen for vaccine. Fortunately, it has been shown that the evolution of influenza is typically in one direction [11,22]. It is

rare to have two or more new clusters in the protein distance map in one season. As experience with the low dimensional sequence clustering is gained, it may be that cluster structure will allow more precise prediction of vaccine efficacy. Despite these issues, the method described here can assist the design of vaccines, and it provides a new tool to analyze influenza viral dynamics. We did not see any false positive results in Table 1.

The current WHO method works quite well in many years. The method discussed here appears to offer an additional tool which may provide additional utility.

## Materials and Methods

### Data sources

Influenza hemagglutinin A(H3N2) sequences before October 1, 2008, and A(H1N1) sequences as of December 5, 2009, were downloaded from NCBI Influenza Virus Resources [24]. All hemagglutinin sequences used in our study are filtered by removing identical sequences. Thus, all groups of identical sequences in the dataset are represented by the oldest sequence in each group. This approach reduces the number of sequences by keeping only the unique sequences in the dataset. The hemagglutinin proteins of 2009 A(H1N1) used in our work are listed in Supplementary Table 3. The numerical labels in Figs. 1 and 2 are the same as the labels in the first column of Supplementary Table 3. Influenza A(H3N2) sequences after October 1, 2008, were downloaded from GISAID database, see Supplementary Table 6. GISAID has the latest H3N2 sequence data.

### Geographical spread pattern of 2009 A(H1N1)

It is believed that the 2009 A(H1N1) virus was most likely originated from Mexico [3]. It first spread to the neighboring country USA and then to other countries. We display this geographical spread pattern in Fig. 1. We take the founder-F1 relationship from Fig. 1, and assume the virus spreads from location of founder to the location of F1. We consider three regions: USA, Mexico and other countries except USA and Mexico. Then we count the cases of spreading from one region to another region. In Supplementary Table 2, we show that we observed many more paths of spreading from the USA to other countries than from other countries to the USA. The major path of spreading is from USA to other countries. This result indicates our directional evolutionary map of Fig. 1 is in good agreement with the pattern of geographical spread.

### Multidimensional scaling

The goal of multidimensional scaling is to represent the distance of proteins by a Euclidean distance in coordinate space. We calculate the distance between proteins  $i$  and  $j$ ,  $d_{ij}$ , by the number of amino acid residue differences divided by the total number of amino acid residues, as defined by Equation 1 in the main text. To do multidimensional scaling, we start with the distance of the proteins. The object of multidimensional scaling is to find the two, or  $p$  in general, directions that best preserve the distances  $d_{ij}$  between the  $N$  proteins

$$F = \sum_{i,j=1}^N (d_{ij} - D_{ij})^2 \quad (2)$$

Here,  $D_{ij} = \|x_i - x_j\|$  is the Euclidean distance between proteins  $i$  and  $j$  in the projected space, and  $\|\bullet\|$  is the vector norm. The algorithm is as follows. Let the matrix  $A = [(a_{ij})]$ , where  $a_{ij} = -\frac{1}{2}d_{ij}^2$ . The eigenvalues of  $A$  are  $\gamma_1, \gamma_2, \dots, \gamma_N$  and  $\gamma_1 \geq \gamma_2 \geq \dots \geq \gamma_N$ . Let  $V^{(1)} = (v_1^{(1)}, v_2^{(1)}, \dots, v_N^{(1)})$  be the eigenvector of  $\gamma_1$  and  $V^{(2)} = (v_1^{(2)}, v_2^{(2)}, \dots, v_N^{(2)})$  be the eigenvector of  $\gamma_2$ . Let  $x = \sqrt{\gamma_1}V^{(1)}$  and  $y = \sqrt{\gamma_2}V^{(2)}$ . The two

coordinates in Figs. 2–6 are  $x$  and  $y$ . The  $x$ -axis in the protein distance map is the largest eigenvector. We take H3N2 2008–2009 season as an example. In Fig. 5(c), we observe two clusters. One cluster is on the right side of figures with  $x$  value positive and another one has negative  $x$  values. We define the consensus sequence of a group of flu strains by taking the most frequent amino acid at each position. We calculate the consensus sequences both for the strains in the cluster on the right and on the left of figure. We found amino acids at four positions (76, 160, 172, 203) are different for these two consensus H3N2 strains, see Supplementary Table 1. Interestingly, the Shannon entropy calculated from all 2008–2009 season sequences at these four positions (0.43, 0.67, 0.59, 0.50) are the largest, which means the diversity at these four position are the largest.

There is software available to run the multidimensional scaling. We use the Matlab function “CMDSCALE” to generate an  $N \times p$  configuration matrix  $Y$ . Rows of  $Y$  are the coordinates of  $N$  points in  $p$ -dimensional space. The “CMDSCALE” also returns a vector  $E$  containing the sorted eigenvalues of what is often referred to as the “scalar product matrix,” which, in the simplest case, is equal to  $YY^T$ . If only two or three of the largest eigenvalues  $E$  are much larger than others, then the matrix  $D$  based on the corresponding columns of  $Y$  nearly reproduces the original distance matrix  $d$ . We used the influenza H3N2 in 2001–2002 season as an example. The five largest of all 180 eigenvalues are 0.0361, 0.0032, 0.0024, 0.0020, 0.0016. The first two largest eigenvalues contribute 70% to the sum of all 180 eigenvalues, which indicates  $p = 2$ . Then, we plot the the  $N$  points in a two-dimensional graph. Each point represents a protein. The Euclidean distance between any two points  $D_{ij}$  on the graph should be equal to or close to the distance of these two proteins. that is,  $D_{ij} \approx d_{ij}$ . As an example, in Supplemental Fig. 1, We show that  $D_{ij}$  and  $d_{ij}$  have a strong linear relationship. A short MATLAB program of multidimensional scaling is as follow.

```
% Multidimensional scaling.
% alignment.aln is a sequence multialignment file
% generated by software ClustalW.
clear
Sequences = multialignread('alignment.aln');
distances = seqpdist(Sequences,'Method','p-distance');
Y = cmdscale(distances);
scatter(Y(:,1), Y(:,2));
```

### $p_{\text{epitope}}$ estimation

The value of  $p_{\text{epitope}}$  is a measure of antigenic distance between influenza A vaccine and circulating strains. The hemagglutinin protein has five epitopes. The dominant epitope for a particular circulating strain in a particular season was taken as that which had the largest fractional change in amino acid sequence relative to the vaccine strain. The value of  $p_{\text{epitope}}$  is defined as the fraction of number of amino acid differences in the dominant epitope to total number of amino acids in the dominant epitope. The antigenic distance between the vaccine strain and the circulating strain is quantified by  $p_{\text{epitope}}$ . By a metaanalysis of historical vaccine efficacy data from over 50 publications, Gupta *et al.* showed in a metaanalysis that the  $p_{\text{epitope}}$  between vaccine strain and circulating strain correlates well with the vaccine efficacy, with  $R^2 > 0.8$  [16]. The value of  $p_{\text{epitope}}$  can be easily calculated from sequence data.

### Biases in the data

There are two biases in the sequence data. First, more isolates are sequenced in recent years. Generally speaking, more sequences make the vaccine selection based on low-dimensional clustering methods more reliable. That is why we compared low-dimensional clustering methods with WHO results only since 1996 in Table 1. To avoid these biases in the generation of the figure of evolution history of influenza for the 40 years (Fig. 3), we choose 20 random isolates for each season, even though the database contains

more sequences in recent years. Second, most isolates are collected in USA. We found that many isolates collected in USA are identical, because of the high sampling rate in USA. To reduce this bias, we collapse redundant strains, keeping only distinct strains.

## Funding


This research was supported by DARPA under the FunBio program.

## References


1. Deem M, Pan K (2009) The epitope regions of H1-subtype influenza A, with application to vaccine efficacy. *Protein Engineering, Design & Selection* 22: 543-546.
2. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. *Science* 325: 197-201.
3. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, et al. (2009) Pandemic potential of a strain of influenza A (H1N1): Early findings. *Science* 324: 1557-1561.
4. Smith G, Vijaykrishna D, Bahl J, Lycett S, Worobey M, et al. (2009) Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza a epidemic. *Nature* 459: 1122.
5. World Health Organization (2009 [cited 2010 January 27]). Pandemic (H1N1) 2009 - update 64. Available from <http://www.who.int/csr/disease/swineflu/updates/en/index.html>.
6. World Health Organization (June 4, 2009). World now at the start of 2009 influenza pandemic. Available from <http://www.who.int/mediacentre/news/statements/2009/>.
7. Drake JW, Holland JJ (1999) Mutation rates among RNA viruses. *Proc Natl Acad Sci USA* 96: 13910-3.
8. Fitch WM, Bush RM, Bender CA, Cox NJ (1997) Long term trends in the evolution of H(3) HA1 human influenza type A. *Proceedings of the National Academy of Sciences of the United States of America* 94: 7712-7718.
9. Webster RG (1998) Influenza: an emerging disease. *Emerging Infectious Diseases* 4: 436-441.
10. Gupta S, Ferguson N, Anderson R (1998) Chaos, persistence, and evolution of strain structure in antigenically diverse infectious agents. *Science* 280: 912.
11. Ferguson N, Galvani A, Bush R (2003) Ecological and immunological determinants of influenza evolution. *Nature* 422: 428.
12. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, et al. (2005) Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. *Nature* 437: 1162-1166.
13. Nelson MI, Holmes EC (2007) The evolution of epidemic influenza. *Nature Reviews Genetics* 8: 196-205.
14. Domingo E, Holland J, Biebricher C (2002) Quasispecies and RNA virus evolution: Principles and consequences. Landes, Austin, TX.

15. Hak E, Nordin J, Wei F, Mullooly J, Poblete S, et al. (2002) Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed health care organizations. *Clinical Infectious Diseases* 35: 370-377.
16. Gupta V, Earl DJ, Deem M (2006) Quantifying influenza vaccine efficacy and antigenic distance. *Vaccine* 24: 3881-3888.
17. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, et al. (2008) Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. *Vaccine* 26: D31 - D34.
18. Skowronski D. Influenza A (H1N1) - worldwide (11): Coincident H3N2 variation. ProMed. 2009 May 5. Available from <http://www.promedmail.org>, archive no. 20090505.1679.
19. Seasonal influenza (H3N2) virus - potential vaccine mismatch. ProMed. 2009 July 24. Available from <http://www.promedmail.org>, archive no. 20090724.2623.
20. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, et al. (2008) The global circulation of seasonal influenza a (H3N2) viruses. *Science* 320: 340-346.
21. Lapedes A, Farber R (2001) The geometry of shape space: Application to influenza. *Journal of Theoretical Biology* 212: 57 - 69.
22. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, et al. (2004) Mapping the antigenic and genetic evolution of influenza virus. *Science* 305: 371-376.
23. Plotkin JB, Dushoff J, Levin SA (2002) Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus. *Proceedings of the National Academy of Sciences of the United States of America* 99: 6263-6268.
24. Bao Y, Bolotov P, Dernovoy D, Kiryutin B, Zaslavsky L, et al. (2008) The influenza virus resource at the national center for biotechnology information. *J Virol* 82: 596-601.
25. FDA (July 23, 2009) Regulatory considerations regarding the use of novel influenza A (H1N1) virus vaccines .
26. Everitt BS, Landau S, Leese M (2001) *Cluster Analysis*. Oxford Univ. Press.
27. Pan K, Subieta K, Deem M (2009) Quantify seasonal H1N1 influenza vaccine efficacy and antigenic distance. .
28. Zhou H, Pophale RS, Deem MW (2010) Computer-assisted vaccine design. In: Wang Q, Tao YJ, editors, *Influenza: Molecular Virology*, Caister Academic Press, chapter 10.
29. (2004) Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine—Colorado, December 2003. *MMWR Morb Mortal Wkly Rep* 53: 8-11.
30. World Health Organization (2009 [cited 2010 January 27]). Recommendations for influenza viruses. Available from <http://www.who.int/csr/disease/influenza/vaccinerecommendations/en/index.html>.
31. Cox N, Bender C (1995) The molecular epidemiology of influenza viruses. *Seminars in virology* 6: 359-370.
32. Santamaria C, Urue A, Videla C, *et al* (2008) Epidemiological study of influenza virus infections in young adult outpatient: Results. *Influenza Resp Viruses* 2: 131-134.


33. (2004) Virology quarterly report Jul-Sep 2004. .
34. Northern hemisphere: Risk of A/Wellington/1/2004(H3N2)-like virus. ProMed. 2004 October 24. Available from <http://www.promedmail.org>, archive no. 20041024.2879.
35. World Health Organization (2005) Wkly Epidemiol Rec 80: 341.
36. Turner JL, Fielding JE, Clothier HJ, Kelly HA (2006) Influenza surveillance in victoria, 2005. Communicable Diseases Intelligence 30: 137.
37. (2005) Influenza Weekly Update 22-38.
38. World Health Organization (1995) Wkly Epidemiol Rec 70: 53.
39. World Health Organization (1996) Wkly Epidemiol Rec 71: 57.
40. World Health Organization (1997) Wkly Epidemiol Rec 72: 57.
41. World Health Organization (1998) Wkly Epidemiol Rec 73: 56.
42. World Health Organization (1999) Wkly Epidemiol Rec 74: 57.
43. World Health Organization (2000) Wkly Epidemiol Rec 75: 61.
44. World Health Organization (2001) Wkly Epidemiol Rec 76: 57.
45. World Health Organization (2002) Wkly Epidemiol Rec 77: 57.
46. World Health Organization (2003) Wkly Epidemiol Rec 78: 57.
47. World Health Organization (2004) Wkly Epidemiol Rec 79: 85.
48. World Health Organization (2005) Wkly Epidemiol Rec 80: 65.
49. World Health Organization (2006) Wkly Epidemiol Rec 81: 81.
50. World Health Organization (2007) Wkly Epidemiol Rec 82: 69.
51. World Health Organization (2008) Wkly Epidemiol Rec 83: 77.
52. World Health Organization (2009) Wkly Epidemiol Rec 84: 65.
53. World Health Organization (2010) Wkly Epidemiol Rec 85: 81.




**Figure 1.** The evolutionary path of 2009 A(H1N1) influenza. Strain #1: A/California/05/2009. Strain #2: A/California/04/2009. Strain #7: A/California/07/2009. Strain #12: A/Texas/05/2009. Strain #28: A/New York/19/2009. For complete strain names, see supplemental material. Strains from the Northern and Southern hemisphere are shown as red dots and blue dots respectively. One branch represents one substitution in the amino acid sequence.



**Figure 2.** (a), Kernel density estimation for the protein distance map of 2009 A(H1N1) influenza as of December 5, 2009. (b), The protein distance map of 2009 A(H1N1) influenza. The vertical and horizontal axes of both figures represent protein distance as defined in Equation 1. A 0.0018 unit of protein distance equals one substitution in the HA protein sequence of H1N1. The height and colors in (a) both represent the density of isolates.




(a)




(b)


**Figure 3.** (a) The protein distance map and (b) corresponding Kernel density estimation of influenza from 1968 to 2007. The vertical and horizontal axes of both figures represent protein distance as defined in Equation 1. A 0.0030 unit of protein distance equals one substitution in the HA1 protein sequence of H3N2. The colors in (a) represent the time of collection of the isolates. The colors and height in (b) represent the density of isolates. Each cluster is named after the first vaccine strain in the cluster. HK68: Hongkong/1/68, EN72: England/42/72, VT75: Victoria/3/75, TX77: Texas/1/77, BK79: Bangkok/1/79, PP82: Philippines/2/82, SC87: Sichuan/2/87, BJ89: Beijing/32/92, SD93: Shandong/9/93, JB94: Johannesburg/33/94, WH95: Wuhan359/95, SN97: Sydney/5/97, PM99: Panama/2007/99, FJ02: Fujian/411/2002;



**Figure 4.** (a) Kernel density estimation and (c) protein distance map for H3N2 viruses between October 1, 2002 and February 1, 2003. (b) Kernel density estimation and (d) protein distance map for H3N2 viruses between October 1, 2001, and September 9, 2002. We plot a dotted line to separate the two clusters. The vertical and horizontal axes of all figures represent protein distance as defined in Equation 1. A 0.0030 unit of protein distance equals one substitution of the HA1 protein sequence of H3N2.



**Figure 5.** (a) Kernel density estimation and (c) protein distance map for H3N2 viruses from October 1, 2008, to June 14, 2009. (b) Kernel density estimation and (d) protein distance map for H3N2 viruses between October 1, 2008, and March 30, 2009. The vertical and horizontal axes of all figures represent protein distance as defined in Equation 1. A 0.0030 unit of protein distance equals one substitution of the HA1 protein sequence of H3N2.



**Figure 6.** (a), Kernel density estimation for the protein distance map for H3N2 viruses between 10/01/2003 and 09/30/2004. (b), Kernel density estimation for the protein distance map for H3N2 viruses between 10/01/2003 and 02/01/2004. (c), Protein distance map for H3N2 viruses between 10/01/2003 and 09/30/2004. We plot a dotted line to separate the two clusters. (d), Protein distance map for H3N2 viruses between 10/01/2003 and 02/01/2004. The vertical and horizontal axes of all figures represent protein distance. A 0.0030 unit of protein distance equals one mutation of the HA1 protein sequence of H3N2.

**Table 1.** Summary of results

Flu season	Vaccine strain from WHO [30]	Our prediction	Circulating H3N2 strain	Circulating subtype
1996-1997	Wuhan/359/95	Wuhan/359/95	Wuhan/359/95	H3
1997-1998	Wuhan/359/95	Wuhan/359/95	Sydney/5/97	H3
1998-1999	Sydney/5/97	Sydney/5/97	Sydney/5/97	H3
1999-2000	Sydney/5/97	Sydney/5/97	Sydney/5/97	H3
2000-2001	Panama/2007/1999	Panama/2007/1999	N/A	H1
2001-2002	Panama/2007/1999	Panama/2007/1999	Panama/2007/1999	H3
2002-2003	Panama/2007/1999	Fujian/411/2002	N/A	H1
2003-2004	Panama/2007/1999	Fujian/411/2002	Fujian/411/2002	H3
2004-2005	Fujian/411/2002	Fujian/411/2002	Fujian/411/2002	H3
2005-2006	California/7/2004	California/7/2004	California/7/2004	H3
2006-2007	Wisconsin/67/2005	Wisconsin/67/2005	Wisconsin/67/2005	H3
2007-2008	Wisconsin/67/2005	Wisconsin/67/2005	N/A	H1
2008-2009	Brisbane/10/2007	Brisbane/10/2007	Brisbane/10/2007	H3
2009-2010	Brisbane/10/2007	BritishColumbia/RV1222/09	BritishColumbia/RV1222/09	H1
2010-2011	Perth/16/2009	BritishColumbia/RV1222/09	N/A	N/A

This table includes the H3N2 vaccine strains, our prediction of dominant strains, the reported dominant circulating H3N2 strains [38–53], and the circulating subtypes in the northern hemisphere [38–53]. Circulating H3N2 strains are absent if the dominant subtype is H1 or influenza B. The reported dominant H3N2 strains and circulating subtypes data are from WHO Weekly Epidemiological Record (<http://www.who.int/wer/en/>).

## Low-dimensional clustering detects incipient dominant influenza strain clusters


Jiankui He<sup>1</sup>, Michael W. Deem<sup>1,2</sup>

**1 Department of Physics & Astronomy, Rice University, Houston, Texas, USA**

**2 Department of Bioengineering, Rice University, Houston, Texas, USA**

**\* E-mail: Corresponding mwdeem@rice.edu**

### Supplementary Data



**Figure 1.** Plot of Euclidean distances of proteins as in Figure 4(d) of main text on  $x$ -axis and plot of distance of corresponding proteins in  $y$ -axis. Closeness to the diagonal measures fidelity of the low dimensional projection. A 0.0030 unit of protein distance equals one mutation of the HA1 protein sequence of H3N2.

Spreading path	Number of cases
USA to Others	32
Others to USA	1
Mexico to Others	1
Others to Mexico	0
Others to others	6

**Table 1.** The geographical spread pattern of 2009 A(H1N1). "Others" refers to other countries except USA and Mexico.

Position in HA1 protein of H3N2	76	160	172	203
Amino acid in consensus strain 1	Glu	Asn	Lys	Asn
hline Amino acid in consensus strain 2	Lys	Lys	Asn	Lys
Shannon Entropy	0.43	0.67	0.59	0.50

**Table 2.** Consensus strain 1 is the calculated from all strains in the cluster on the right side of Figure 5(c). Consensus strain 2 is the calculated from all strains in the cluster on the left side of Figure 5(c).

**Table 3.** The 2009 A(H1N1) (swine flu) sequences in Figure 1. Data are from NCBI Influenza Virus Resources.

Label	Accession number	Country	Collection date (mm/dd/yyyy)	Virus name
1	ACP41926	USA	3/30/2009	A/California/05/2009
2	ACP41105	USA	4/1/2009	A/California/04/2009
3	ACR09364	Mexico	4/2/2009	A/Mexico/4108/2009
4	ACR09372	Mexico	4/2/2009	A/Mexico/3955/2009
5	ACQ99613	Mexico	4/2/2009	A/Mexico/4108/2009
6	ACP44189	USA	4/9/2009	A/California/07/2009
7	ACP41953	USA	4/9/2009	A/California/07/2009
8	ACT36657	USA	4/14/2009	A/Texas/04/2009
9	ACR49285	USA	4/14/2009	A/Texas/04/2009
10	ACU29959	USA	4/15/2009	A/San Antonio/PR922/2009
11	ACQ83310	USA	4/15/2009	A/Texas/15/2009
12	ACP41934	USA	4/15/2009	A/Texas/05/2009
13	ACQ99610	Mexico	4/19/2009	A/Mexico/4603/2009
14	ACR09375	Mexico	4/20/2009	A/Mexico/4635/2009
15	ACR67180	USA	4/21/2009	A/California/13/2009
16	ACT36662	USA	4/22/2009	A/California/12/2009
17	ACQ76383	USA	4/22/2009	A/Indiana/09/2009
18	ACR67176	USA	4/23/2009	A/Texas/10/2009
19	ACU29969	USA	4/23/2009	A/San Antonio/PR923/2009
20	ACR18983	USA	4/24/2009	A/Kansas/03/2009
21	ACR18990	USA	4/24/2009	A/New York/31/2009
22	ACR18980	USA	4/24/2009	A/Texas/08/2009
23	ACQ63286	USA	4/24/2009	A/Ohio/07/2009
24	ACQ73385	Canada	4/24/2009	A/Canada-NS/RV1535/2009
25	ACQ76340	USA	4/24/2009	A/Kansas/03/2009
26	ACQ76386	USA	4/24/2009	A/Ohio/07/2009
27	ACR49292	USA	4/24/2009	A/California/11/2009
28	ACP44147	USA	4/25/2009	A/New York/19/2009
29	ACT36665	USA	4/25/2009	A/New York/45/2009
30	ACQ63209	USA	4/25/2009	A/New York/12/2009
31	ACR18986	USA	4/25/2009	A/New York/11/2009
32	ACR18987	USA	4/25/2009	A/New York/09/2009
33	ACR18994	USA	4/25/2009	A/New York/12/2009
34	ACR67173	USA	4/25/2009	A/New York/35/2009
35	ACR67169	USA	4/26/2009	A/South Carolina/10/2009
36	ACQ76333	USA	4/26/2009	A/South Carolina/09/2009
37	ACQ76362	USA	4/26/2009	A/Arizona/02/2009
38	ACR49284	USA	4/26/2009	A/South Carolina/09/2009
39	ACR08534	USA	4/27/2009	A/Texas/23/2009
40	ACR08429	USA	4/27/2009	A/New York/3012/2009
41	ACR08526	USA	4/27/2009	A/Florida/04/2009
42	ACR49289	USA	4/27/2009	A/Arizona/04/2009
43	ACR38825	USA	4/27/2009	A/Georgia/01/2009

44	ACR18991	USA	4/27/2009	A/Washington/12/2009
45	ACT68105	Mexico	4/27/2009	A/Mexico/InDRE13547/2009
46	ACQ84467	USA	4/27/2009	A/New York/1682/2009
47	ACR67194	USA	4/28/2009	A/Delaware/08/2009
48	ACR15621	United Kingdom	4/28/2009	A/England/195/2009
49	ACR49294	USA	4/28/2009	A/Delaware/05/2009
50	ACS94554	USA	4/28/2009	A/Delaware/06/2009
51	ACS94543	USA	4/28/2009	A/Delaware/07/2009
52	ACR56450	USA	4/28/2009	A/New York/3199/2009
53	ACT33094	Germany	4/29/2009	A/Bayern/62/2009
54	ACT68103	Mexico	4/29/2009	A/Mexico/InDRE13494/2009
55	ACR43957	France	4/29/2009	A/Paris/2573/2009
56	ACR67179	USA	4/30/2009	A/Kentucky/05/2009
57	ACR43939	France	4/30/2009	A/Paris/2590/2009
58	ACR39453	USA	4/30/2009	A/New York/3232/2009
59	ACR18920	Hong Kong	4/30/2009	A/Hong Kong/01/2009
60	ACT36664	USA	4/30/2009	A/California/19/2009
61	ACT36651	USA	4/30/2009	A/Tennessee/07/2009
62	ACR81633	France	5/1/2009	A/Paris/2591/2009
63	ACS27239	USA	5/1/2009	A/New York/3307/2009
64	ACU13100	USA	5/1/2009	A/California/27/2009
65	ACT36660	USA	5/1/2009	A/California/20/2009
66	ACR67178	USA	5/4/2009	A/Vermont/03/2009
67	ACU13096	USA	5/5/2009	A/Texas/30/2009
68	ACS72650	USA	5/5/2009	A/Michigan/05/2009
69	ACS78026	USA	5/6/2009	A/New York/3351/2009
70	ACS91400	France	5/6/2009	A/Strasbourg/2611/2009
71	ACT68109	Canada	5/7/2009	A/Canada-QC/RV1759/2009
72	ACT68111	Canada	5/8/2009	A/Canada-SK/RV1793/2009
73	ACR56352	Sweden	5/8/2009	A/Stockholm/29/2009
74	ACR32996	Finland	5/10/2009	A/Finland/553/2009
75	ACR38877	China	5/10/2009	A/Shandong/1/2009
76	ACS77996	USA	5/14/2009	A/New York/3463/2009
77	ACT86049	USA	5/16/2009	A/New York/3502/2009
78	ACR46991	Japan	5/16/2009	A/Osaka/1/2009
79	ACS91402	France	5/17/2009	A/Paris/2650/2009
80	ACS36645	China	5/18/2009	A/GuangzhouSB/01/2009
81	ACS72646	USA	5/19/2009	A/Arizona/09/2009
82	ACT68114	Canada	5/20/2009	A/Canada-MB/RV1964/2009
83	ACT82512	Brazil	5/20/2009	A/Sao Paulo/2056/2009
84	ACS34967	Japan	5/21/2009	A/Sakai/2/2009
85	ACT68117	Canada	5/21/2009	A/Canada-MB/RV1982/2009
86	ACR67262	Italy	5/21/2009	A/Milan/UHSR1/2009
87	ACU29999	Taiwan	5/22/2009	A/Taiwan/T1339/2009
88	ACS34968	Japan	5/22/2009	A/Shiga/1/2009
89	ACS27770	Russia	5/22/2009	A/Kaluga/01/2009
90	ACS91399	France	5/22/2009	A/Paris/2670/2009

91	ACR54964	China	5/23/2009	A/Zhejiang/1/2009
92	ACR67254	China	5/23/2009	A/Beijing/4/2009
93	ACT68101	Canada	5/24/2009	A/Canada-MB/RV2023/2009
94	ACR78588	Russia	5/26/2009	A/Moscow/IIV02/2009
95	ACS50088	Finland	5/26/2009	A/Finland/554/2009
96	ACT33123	Brazil	5/28/2009	A/Mato Grosso/2329/2009
97	ACU30009	Taiwan	5/28/2009	A/Taiwan/T1773/2009
98	ACT68118	Canada	5/28/2009	A/Canada-MB/RV2013/2009
99	ACT79625	China	5/28/2009	A/Shanghai/60T/2009
100	ACT82514	Brazil	5/29/2009	A/Sao Paulo/2261/2009
101	ACR83538	China	5/29/2009	A/Guangdong/03/2009
102	ACT21932	Sweden	5/29/2009	A/Stockholm/31/2009
103	ACS68822	China	5/31/2009	A/Zhejiang/2/2009
104	ACT21971	Sweden	6/1/2009	A/Stockholm/35/2009
105	ACS94551	USA	6/1/2009	A/Rhode Island/04/2009
106	ACS54262	Japan	6/2/2009	A/Tokushima/1/2009
107	ACS91398	France	6/2/2009	A/Paris/2722/2009
108	BAH95823	Japan	6/3/2009	A/Saitama/55/2009
109	ACS45035	USA	6/5/2009	A/California/04/2009
110	ACT79624	China	6/6/2009	A/Shanghai/143T/2009
111	ACT83737	Italy	6/8/2009	A/Ancona/01/2009
112	ACT10316	Hong Kong	6/11/2009	A/Hong Kong/2369/2009
113	ACT83738	Italy	6/11/2009	A/Ancona/02/2009
114	ACS92600	Japan	6/16/2009	A/Utsunomiya/1/2009
115	ACU17389	USA	6/17/2009	A/New York/4197/2009
116	ACT79183	USA	6/18/2009	A/Bethesda/SP508/2009
117	ACS45017	China	6/18/2009	A/Nanjing/1/2009
118	ACU30112	USA	6/18/2009	A/Silver Spring/SP509/2009
119	ACU30121	USA	6/18/2009	A/Silver Spring/SP510/2009
120	ACT22055	Chile	6/19/2009	A/Puerto Montt/Bio87/2009
121	ACU30073	Colombia	6/25/2009	A/Bogota/0466N/2009
122	ACU13129	China	6/29/2009	A/Changsha/78/2009
123	ACT79133	Japan	6/29/2009	A/Japan/1070/2009
124	ACT66162	Singapore	6/30/2009	A/Singapore/TLL01/2009
125	ACT83739	Italy	7/1/2009	A/Ancona/04/2009
126	ACT82516	Brazil	7/3/2009	A/Sao Paulo/43812/2009
127	ACT83741	Italy	7/12/2009	A/Ancona/05/2009

**Table 4.** The H3N2 sequences in Figure 4(c). Data are from NCBI Influenza Virus Resources.

Label	Accession number	Country	Collection date (mm/dd/yyyy)	Virus name
1	ACF36384	Hong Kong	10/1/2002	A/Hong Kong/CUHK50200/2002
2	ACC66393	Australia	10/2/2002	A/VICTORIA/432/2002
3	ABI92632	Australia	10/15/2002	A/Western Australia/36/2002
4	ACC67637	France	10/15/2002	A/LYON/19989/2002
5	ACC77932	USA	10/30/2002	A/Hawaii/HI-02-3736/2002
6	ACC66357	South Korea	10/31/2002	A/Kwangju/219/2002
7	ACC77933	USA	11/1/2002	A/New York/28/2002
8	ACC77934	Bulgaria	11/2/2002	A/Sofia/343/2002
9	ACC67720	Bulgaria	11/2/2002	A/SOFIA/344/2002
10	ACC66354	South Korea	11/14/2002	A/Incheon/260/2002
11	ACC66358	South Korea	11/18/2002	A/KYONGBUK/304/2002
12	ACC66369	South Korea	11/20/2002	A/Pusan/504/2002
13	ACC66345	South Korea	11/20/2002	A/Cheonnam/323/2002
14	ACC77936	China	11/21/2002	A/Beijing/178-NEW-AGN/2002
15	ACC77937	Philippines	11/21/2002	A/Philippines/PH-1159050/2002
16	ACC66344	South Korea	11/29/2002	A/Cheju/274/2002
17	ACC77939	China	12/1/2002	A/Anhui/550/2002
18	ACC67682	France	12/1/2002	A/PARIS/207/2002
19	ACC77940	USA	12/2/2002	A/Alaska/AK-RSP-02-753/2002
20	ACN32523	Italy	12/2/2002	A/Genoa/1/2002
21	ABO37625	South Korea	12/2/2002	A/Korea/770/2002
22	ACC77942	USA	12/3/2002	A/California/CA-T02-3025/2002
23	ACC66374	Singapore	12/7/2002	A/SINGAPORE/44/2002
24	ACC77944	Taiwan	12/9/2002	A/Taiwan/TW-1521/2002
25	ACC77945	Turkey	12/13/2002	A/Turkey/TU-RSP-02-1035/2002
26	ACC77946	Taiwan	12/15/2002	A/Taiwan/TW-1522/2002
27	ACF36415	Hong Kong	12/18/2002	A/Hong Kong/CUHK53123/2002
28	ACC77948	China	12/20/2002	A/Beijing/301/2002
29	ACC77949	USA	12/22/2002	A/Hawaii/HI-02-4051/2002
30	ACC67657	Latvia	12/23/2002	A/LATVIA/13794/2002
31	ACC77950	USA	12/24/2002	A/Hawaii/HI-02-4055/2002
32	ABO10182	Japan	12/25/2002	A/Kumamoto/102/2002E
33	ACC77951	USA	12/28/2002	A/Hawaii/HI-02-4092/2002
34	ACC77952	USA	12/29/2002	A/North Carolina/NC-C02-4981/2002
35	ACC66516	Singapore	1/7/2003	A/SINGAPORE/7/2003
36	ACC66445	United Kingdom	1/8/2003	A/ENGLAND/1/2003
37	ACC67602	USA	1/8/2003	A/Washington/WA-V130811/2003
38	ACC67661	Germany	1/14/2003	A/BAYERN/1/2003
39	ACC67377	Egypt	1/14/2003	A/Egypt/EG-2002923226/2003
40	ACC67440	USA	1/15/2003	A/Michigan/MI-VC76/2003
41	ACC66517	Singapore	1/15/2003	A/SINGAPORE/16/2003
42	ABO20960	Australia	1/15/2003	A/Sydney/015/03
43	ACC66485	USA	1/16/2003	A/MEMPHIS/1/2003
44	ACC66486	USA	1/16/2003	A/Memphis/2/2003

45	ACF36424	Hong Kong	1/18/2003	A/Hong Kong/CUHK5627/2003
46	ACF36426	Hong Kong	1/20/2003	A/Hong Kong/CUHK5723/2003
47	ABB03112	USA	1/20/2003	A/New York/485/2003
48	ACC67688	Ireland	1/24/2003	A/IRELAND/1215/2003
49	ACC66560	USA	1/28/2003	A/WYOMING/2/2003
50	ACC66521	Bulgaria	2/1/2003	A/SOFIA/141/2003

**Table 5.** The H3N2 sequences in Figure 4(d). Data are from NCBI Influenza Virus Resources.

Label	Accession number	Country	Collection date (mm/dd/yyyy)	Virus name
1	ABI92544	Australia	10/2/2001	A/Western Australia/17/2001
2	ACC66320	Australia	10/29/2001	A/South Australia/102/2001
3	ACF36383	Hong Kong	11/8/2001	A/Hong Kong/CUHK50080/2001
4	AAX56570	USA	11/22/2001	A/New York/71/2001
5	AAX56490	USA	11/27/2001	A/New York/124/2001
6	AAX11625	USA	12/15/2001	A/New York/83/2001
7	AAX35861	USA	12/23/2001	A/New York/131/2001
8	AAY28335	USA	12/25/2001	A/New York/94/2001
9	ACF36396	Hong Kong	12/26/2001	A/Hong Kong/CUHK51424/2001
10	ACF36397	Hong Kong	12/26/2001	A/Hong Kong/CUHK51431/2001
11	ACF36398	Hong Kong	12/28/2001	A/Hong Kong/CUHK51490/2001
12	AAX12761	USA	12/29/2001	A/New York/84/2001
13	AAX56440	USA	12/31/2001	A/New York/85/2001
14	ACC77886	China	1/1/2002	A/Tianjin/5/2002
15	ACC77887	USA	1/1/2002	A/Louisiana/2/2002
16	ACC77888	USA	1/4/2002	A/Oklahoma/2/2002
17	ABA42335	USA	1/4/2002	A/New York/403/2002
18	ACC77889	USA	1/5/2002	A/Utah/6/2002
19	ACC77891	China	1/7/2002	A/Beijing/20/2002
20	ABA42989	USA	1/7/2002	A/New York/405/2002
21	ACC66370	Singapore	1/7/2002	A/SINGAPORE/2/2002
22	ACC66386	Australia	1/9/2002	A/VICTORIA/103/2002
23	ACC66387	Australia	1/9/2002	A/VICTORIA/105/2002
24	ACF36405	Hong Kong	1/10/2002	A/Hong Kong/CUHK5250/2002
25	ACF36406	Hong Kong	1/10/2002	A/Hong Kong/CUHK5251/2002
26	ACC77895	China	1/10/2002	A/Wuhan/12/2002
27	ABA42368	USA	1/11/2002	A/New York/408/2002
28	ACC66544	Australia	1/12/2002	A/VICTORIA/102/2003
29	ACF36411	Hong Kong	1/12/2002	A/Hong Kong/CUHK5296/2002
30	AAX56460	USA	1/12/2002	A/New York/89/2002
31	ABR15962	New Zealand	1/14/2002	A/Auckland/614/2002
32	ABA42379	USA	1/14/2002	A/New York/409/2002
33	AAY47023	USA	1/14/2002	A/New York/125/2002
34	ABA42487	USA	1/16/2002	A/New York/418/2002
35	AAY28648	USA	1/16/2002	A/New York/107/2002
36	ACC77896	China	1/17/2002	A/Wuhan/16/2002
37	ABR14636	Norway	1/17/2002	A/Oslo/398/2002
38	AAX12771	USA	1/17/2002	A/New York/91/2002
39	AAX47525	USA	1/18/2002	A/New York/96/2002
40	ABA42498	USA	1/18/2002	A/New York/419/2002
41	ACC77897	Hong Kong	1/19/2002	A/Hong Kong/1550/2002
42	AAX56580	USA	1/20/2002	A/New York/106/2002
43	AAX12791	USA	1/22/2002	A/New York/100/2002
44	ABA42401	USA	1/22/2002	A/New York/411/2002

45	ACC77898	USA	1/23/2002	A/New York/16/2002
46	ACC66371	Singapore	1/24/2002	A/SINGAPORE/7/2002
47	AAX56510	USA	1/27/2002	A/New York/132/2002
48	ABB04983	USA	1/28/2002	A/New York/420/2002
49	AAX11635	USA	1/29/2002	A/New York/110/2002
50	AAAY44641	USA	1/30/2002	A/New York/118/2002
51	ABG48082	New Zealand	1/31/2002	A/Waikato/2/2002
52	AAX56590	USA	1/31/2002	A/New York/108/2002
53	AAX12801	USA	1/31/2002	A/New York/113/2002
54	ABA42412	USA	2/1/2002	A/New York/412/2002
55	ABI21508	USA	2/1/2002	A/New York/C4/2002
56	ACC77901	USA	2/1/2002	A/Massachusetts/2/2002
57	ACC77902	USA	2/4/2002	A/New York/18/2002
58	AAAY28014	USA	2/4/2002	A/New York/101/2002
59	AAX56470	USA	2/6/2002	A/New York/90/2002
60	ABG48093	New Zealand	2/10/2002	A/Wellington/6/2002
61	AAAY44620	USA	2/12/2002	A/New York/75/2002
62	AAX47515	USA	2/12/2002	A/New York/129/2002
63	AAX35871	USA	2/14/2002	A/New York/135/2002
64	ACC66327	Australia	2/18/2002	A/BRISBANE/3/2002
65	AAX57784	USA	2/19/2002	A/New York/120/2002
66	ACC77904	USA	2/21/2002	A/North Carolina/6/2002
67	ACC66353	Japan	2/23/2002	A/FUKUOKA/15/2002
68	ACC77905	USA	2/24/2002	A/Illinois/1/2002
69	BAG28225	Japan	2/25/2002	A/Morioka/34/2002
70	AAAY28325	USA	2/26/2002	A/New York/88/2002
71	AAX12781	USA	2/26/2002	A/New York/95/2002
72	ABA42476	USA	2/28/2002	A/New York/416/2002
73	AAX35841	USA	3/1/2002	A/New York/86/2002
74	ACF36221	Hong Kong	3/1/2002	A/Hong Kong/CUHK13216/2002
75	BAG28226	Japan	3/1/2002	A/Morioka/52/2002
76	AAZ38539	USA	3/1/2002	A/New York/126/2002
77	ACF36222	Hong Kong	3/3/2002	A/Hong Kong/CUHK13249/2002
78	ACF36223	Hong Kong	3/4/2002	A/Hong Kong/CUHK13278/2002
79	ABS50064	New Zealand	3/4/2002	A/Auckland/615/2002
80	ACC77909	Thailand	3/4/2002	A/Thailand/128400/2002
81	ACC77910	USA	3/5/2002	A/Hawaii/4/2002
82	ACC77911	Hong Kong	3/6/2002	A/Hong Kong/121715/2002
83	AAAY98077	USA	3/7/2002	A/New York/276/2002
84	ACC66376	Thailand	3/8/2002	A/SONGKHLA/107/2002
85	AAX57734	USA	3/11/2002	A/New York/130/2002
86	AAAY28405	USA	3/21/2002	A/New York/122/2002
87	ACC77912	Hong Kong	3/25/2002	A/Hong Kong/568/2002
88	ACC66323	Thailand	3/25/2002	A/BANGKOK/109/2002
89	ACC77913	USA	4/3/2002	A/Washington/3/2002
90	ACC77914	Brazil	4/4/2002	A/Ceara/177/2002
91	ACF36278	Hong Kong	4/4/2002	A/Hong Kong/CUHK21713/2002

92	ACC66361	New Caledonia	4/4/2002	A/New Caledonia/6/2002
93	ACF36281	Hong Kong	4/8/2002	A/Hong Kong/CUHK21742/2002
94	ACF36284	Hong Kong	4/11/2002	A/Hong Kong/CUHK21957/2002
95	ABG37417	New Zealand	4/12/2002	A/Waikato/5/2002
96	ACC77915	USA	4/17/2002	A/Nebraska/12/2002
97	ABC42871	New Zealand	4/26/2002	A/Canterbury/01/2002
98	ABC67850	New Zealand	5/2/2002	A/Canterbury/14/2002
99	ACF36299	Hong Kong	5/10/2002	A/Hong Kong/CUHK23113/2002
100	ACF36300	Hong Kong	5/10/2002	A/Hong Kong/CUHK23162/2002
101	ACF36301	Hong Kong	5/12/2002	A/Hong Kong/CUHK23180/2002
102	ACC77916	Argentina	5/14/2002	A/Argentina/1/2002
103	ACC77917	Peru	5/14/2002	A/Peru/3029/2002
104	ACC77918	China	5/14/2002	A/Guangzhou/394/2002
105	ACC66394	Australia	5/20/2002	A/VICTORIA/506/2002
106	ACC77919	Brazil	5/23/2002	A/Brazil/1727/2002
107	ACF36302	Hong Kong	6/1/2002	A/Hong Kong/CUHK24044/2002
108	ACF36303	Hong Kong	6/2/2002	A/Hong Kong/CUHK24054/2002
109	ACF36304	Hong Kong	6/3/2002	A/Hong Kong/CUHK24114/2002
110	ACF36305	Hong Kong	6/4/2002	A/Hong Kong/CUHK24167/2002
111	ACC77920	Hong Kong	6/6/2002	A/Hong Kong/1143/2002
112	ABI92335	New Zealand	6/7/2002	A/Dunedin/1/2002
113	ACC66328	Australia	6/7/2002	A/BRISBANE/5/2002
114	ABC50255	New Zealand	6/8/2002	A/Canterbury/47/2002
115	ABR28856	New Zealand	6/8/2002	A/Auckland/608/2002
116	ABC50299	New Zealand	6/10/2002	A/Canterbury/53/2002
117	ABC50288	New Zealand	6/11/2002	A/Canterbury/50/2002
118	ACC66347	New Zealand	6/13/2002	A/CHRISTCHURCH/37/2002
119	ABC68049	New Zealand	6/13/2002	A/South Canterbury/37/2002
120	ABG37428	New Zealand	6/17/2002	A/Wellington/38/2002
121	ABC67989	New Zealand	6/20/2002	A/Canterbury/33/2002
122	ACC66329	Australia	6/20/2002	A/BRISBANE/6/2002
123	ABG88806	Australia	6/25/2002	A/Western Australia/23/2002
124	ABC67653	New Zealand	6/27/2002	A/Canterbury/57/2002
125	ACC77922	Brazil	6/27/2002	A/Brazil/1732/2002
126	ABC85952	New Zealand	6/30/2002	A/Canterbury/60/2002
127	ABG37450	New Zealand	7/1/2002	A/Waikato/21/2002
128	ACC66324	Thailand	7/1/2002	A/BANGKOK/190/2002
129	ACF36339	Hong Kong	7/1/2002	A/Hong Kong/CUHK33047/2002
130	ABC50321	New Zealand	7/2/2002	A/Canterbury/59/2002
131	ACF36340	Hong Kong	7/2/2002	A/Hong Kong/CUHK33079/2002
132	ACF36341	Hong Kong	7/2/2002	A/Hong Kong/CUHK33106/2002
133	ACC66373	Singapore	7/2/2002	A/SINGAPORE/29/2002
134	ABI92346	New Zealand	7/3/2002	A/Waikato/23/2002
135	ACC66381	Australia	7/4/2002	A/SYDNEY/23/2002
136	ABC68093	New Zealand	7/6/2002	A/Canterbury/72/2002
137	ABC85919	New Zealand	7/6/2002	A/Canterbury/70/2002
138	ACC66380	Australia	7/7/2002	A/SYDNEY/21/2002

139	ABG26956	New Zealand	7/9/2002	A/Dunedin/10/2002
140	ACC66321	New Zealand	7/9/2002	A/AUCKLAND/26/2002
141	ABC67543	New Zealand	7/9/2002	A/Canterbury/79/2002
142	ABC50376	New Zealand	7/9/2002	A/Canterbury/81/2002
143	ABI92555	Australia	7/10/2002	A/Western Australia/25/2002
144	ABC50354	New Zealand	7/11/2002	A/Canterbury/75/2002
145	ABC50365	New Zealand	7/11/2002	A/Canterbury/80/2002
146	ABG48137	New Zealand	7/15/2002	A/Wellington/71/2002
147	ACC66330	Australia	7/15/2002	A/BRISBANE/22/2002
148	ACC66331	Australia	7/17/2002	A/BRISBANE/45/2002
149	ACC77923	Philippines	7/17/2002	A/Philippines/160283/2002
150	ACC66367	Philippines	7/18/2002	A/PHILIPPINES/471/2002
151	ABK39951	Australia	7/21/2002	A/Western Australia/27/2002
152	ABG88630	New Zealand	7/23/2002	A/Waikato/36/2002
153	ACC77926	Hong Kong	7/26/2002	A/Hong Kong/1510/2002
154	ABI92577	Australia	8/6/2002	A/Western Australia/28/2002
155	ACC66335	Australia	8/8/2002	A/BRISBANE/144/2002
156	ACC77928	Brazil	8/9/2002	A/Brazil/2458/2002
157	ABH01014	China	8/11/2002	A/Fujian/411/2002
158	ACC66336	Australia	8/11/2002	A/BRISBANE/157/2002
159	ACC66352	China	8/11/2002	A/Fujian/411/2002
160	ABP51971	China	8/11/2002	A/Fujian/411/2002
161	ABG88641	New Zealand	8/12/2002	A/Dunedin/18/2002
162	ABK80179	Australia	8/13/2002	A/Queensland/23/2002
163	ABL67308	Australia	8/13/2002	A/Queensland/27/2002
164	ACC66338	Australia	8/13/2002	A/BRISBANE/192/2002
165	ACC77929	India	8/16/2002	A/India/25502/2002
166	ABI92599	Australia	8/19/2002	A/Western Australia/30/2002
167	ABG48170	New Zealand	8/20/2002	A/Wellington/79/2002
168	ACC66364	Australia	8/21/2002	A/PERTH/49/2002
169	ACC66391	Australia	8/22/2002	A/VICTORIA/235/2002
170	ABG37472	New Zealand	8/23/2002	A/Waikato/58/2002
171	ABN51154	Australia	8/28/2002	A/Western Australia/34/2002
172	ACC66322	New Zealand	9/3/2002	A/AUCKLAND/57/2002
173	ACC66342	Australia	9/4/2002	A/BRISBANE/312/2002
174	ABR15940	New Zealand	9/9/2002	A/Auckland/611/2002
175	ACC66360	Malaysia	9/9/2002	A/MALAYSIA/145/2002
176	ACC66379	Australia	9/15/2002	A/South Australia/154/2002
177	ACC66392	Australia	9/16/2002	A/VICTORIA/254/2002
178	ACC66383	Taiwan	9/25/2002	A/TAIWAN/8/2002
179	ABI92621	Australia	9/29/2002	A/Western Australia/35/2002
180	ACC66365	Australia	9/29/2002	A/PERTH/89/2002

**Table 6.** The sequences of H3N2 viruses after 10/01/2008. Data are from GISAID. The first column label is the same as used in Figure 5.

Label	EPI ID	Country	Collection date (mm/dd/yyyy)	Virus name
1 1	EPI187670	Japan	4/2/2009	A/AICHI/158/2009
2	EPI187671	Japan	4/9/2009	A/AICHI/161/2009
3	EPI169724	Japan	11/26/2008	A/AKITA/12/2008
4	EPI187672	Japan	5/27/2009	A/AKITA/34/2009
5	EPI185826	USA	2/27/2009	A/Arizona/08/2009
6	EPI185829	USA	2/25/2009	A/Arizona/11/2009
7	EPI185805	Russia	3/23/2009	A/Astrakhan/7/2009
8	EPI185723	China	2/10/2009	A/Beijing-Xicheng/1108/2009
9	EPI189216	Australia	4/28/2009	A/Brisbane/53/2009
10	EPI185704	Canada	3/15/2009	A/British Columbia/RV1222/2009
11	EPI185707	Canada	3/15/2009	A/British Columbia/RV1223/2009
12	EPI187312	Japan	5/1/2009	A/CHIBA-C/42/2009
13	EPI187313	Japan	1/16/2009	A/CHIBA-C/7/2009
14	EPI175111	USA	12/20/2008	A/California/10/2008
15	EPI185831	USA	1/1/2009	A/Colorado/01/2009
16	EPI169244	USA	10/15/2008	A/Colorado/03/2008
17	EPI172436	USA	10/29/2008	A/Colorado/04/2008
18	EPI185834	USA	1/16/2009	A/Colorado/05/2009
19	EPI185837	USA	1/21/2009	A/Colorado/06/2009
20	EPI175119	USA	12/17/2008	A/Colorado/12/2008
21	EPI175120	USA	12/24/2008	A/Colorado/15/2008
22	EPI187314	Japan	12/15/2008	A/EHIME/36/2008
23	EPI187315	Japan	1/19/2009	A/EHIME/9/2009
24	EPI187317	Japan	12/26/2008	A/FUKUOKA-C/39/2008
25	EPI187319	Japan	12/26/2008	A/FUKUSHIMA/124/2008
26	EPI185726	China	11/26/2008	A/Fujian-Siming/1242/2008
27	EPI185729	China	3/3/2009	A/Fujian-Tongan/142/2009
28	EPI187320	Japan	1/28/2009	A/GIFU-C/37/2009
29	EPI187321	Japan	1/28/2009	A/GIFU-C/38/2009
30	EPI172442	Guam	10/27/2008	A/Guam/7124/2008
31	EPI187322	Japan	2/3/2009	A/HIROSHIMA-C/20/2009
32	EPI187323	Japan	1/6/2009	A/HIROSHIMA-C/7/2009
33	EPI187674	Japan	5/26/2009	A/HIROSHIMA/148/2009
34	EPI187675	Japan	6/10/2009	A/HIROSHIMA/154/2009
35	EPI187324	Japan	12/6/2008	A/HOKKAIDO/9/2008
36	EPI187325	Japan	11/29/2008	A/HYOGO/6/2008
37	EPI187326	Japan	12/11/2008	A/HYOGO/99/2008
38	EPI185840	USA	1/6/2009	A/Hawaii/02/2009
39	EPI185842	USA	1/30/2009	A/Hawaii/05/2009
40	EPI185845	USA	3/28/2009	A/Hawaii/06/2009
41	EPI185851	USA	3/30/2009	A/Hawaii/07/2009
42	EPI185848	USA	3/30/2009	A/Hawaii/07/2009
43	EPI185854	USA	2/11/2009	A/Hawaii/10/2009

44	EPI185857	USA	4/15/2009	A/Hawaii/14/2009
45	EPI185860	USA	4/19/2009	A/Hawaii/15/2009
46	EPI185863	USA	4/20/2009	A/Hawaii/16/2009
47	EPI172430	USA	11/10/2008	A/Hawaii/47/2008
48	EPI185732	China	2/1/2009	A/Heilongjiang-Nangang/134/2009
49	EPI185735	China	2/10/2009	A/Heilongjiang-Xiangfang/163/2009
50	EPI185779	Honduras	5/5/2009	A/Honduras/56/2009
51	EPI185782	Honduras	5/6/2009	A/Honduras/639/2009
52	EPI185738	China	2009/00/00	A/Hong Kong/03/2009
53	EPI185741	China	4/7/2009	A/Hong Kong/1999/2009
54	EPI185744	China	4/7/2009	A/Hong Kong/2000/2009
55	EPI185747	China	4/6/2009	A/Hong Kong/2007/2009
56	EPI185750	China	4/5/2009	A/Hong Kong/2008/2009
57	EPI175154	China	10/8/2008	A/Hong Kong/3134/2008
58	EPI185754	China	1/6/2009	A/Hong Kong/40/2009
59	EPI187329	Japan	1/6/2009	A/IWATE/4/2009
60	EPI185866	USA	3/14/2009	A/Idaho/04/2009
61	EPI172414	USA	10/7/2008	A/Idaho/17/2008
62	EPI171404	USA	10/16/2008	A/Idaho/18/2008
63	EPI185868	USA	1/19/2009	A/Indiana/02/2009
64	EPI185871	USA	4/15/2009	A/Indiana/10/2009
65	EPI185873	USA	1/2/2009	A/Iowa/03/2009
66	EPI173166	Kenya	10/8/2008	A/Isiolo/7514/2008
67	EPI185785	Jamaica	4/28/2009	A/Jamaica/2970/2009
68	EPI185757	China	3/12/2009	A/Jiangsu-Quanshan/114/2009
69	EPI187676	China	2/13/2009	A/Jiangsu-quanshan/38/2009
70	EPI187330	China	2/24/2009	A/Jiangxi-xihu/37/2009
71	EPI169726	Japan	11/12/2008	A/KANAGAWA/61/2008
72	EPI169727	Japan	11/12/2008	A/KANAGAWA/65/2008
73	EPI187331	Japan	1/26/2009	A/KOBE/33/2009
74	EPI187332	Japan	12/17/2008	A/KOBE/61/2008
75	EPI187333	Japan	4/5/2009	A/KOBE/84/2009
76	EPI187334	Japan	1/23/2009	A/KOCHI/35/2009
77	EPI187335	Japan	12/6/2008	A/KOCHI/53/2008
78	EPI187337	Japan	1/23/2009	A/KYOTO/12/2009
79	EPI187338	Japan	11/25/2008	A/KYOTO/19/2008
80	EPI187339	Japan	11/19/2008	A/KYOTO/20/2008
81	EPI187677	Japan	5/22/2009	A/KYOTO/30/2009
82	EPI187340	Japan	1/16/2009	A/KYOTO/8/2009
83	EPI185875	USA	2009/00/00	A/Kentucky/02/2009
84	EPI185789	Kenya	10/3/2008	A/Kenya/2234/2008
85	EPI185791	Kenya	10/15/2008	A/Kenya/2282/2008
86	EPI185793	Kenya	10/21/2008	A/Kenya/2297/2008
87	EPI173167	Kenya	11/7/2008	A/Kericho/7532/2008
88	EPI173168	Kenya	11/10/2008	A/Kericho/7533/2008
89	EPI173169	Kenya	11/10/2008	A/Kericho/7534/2008
90	EPI173173	Kenya	10/6/2008	A/Kisii/7544/2008

91	EPI173174	Kenya	10/8/2008	A/Kisii/7546/2008
92	EPI173175	Kenya	10/14/2008	A/Kisii/7548/2008
93	EPI173176	Kenya	10/15/2008	A/Kisii/7549/2008
94	EPI173177	Kenya	10/16/2008	A/Kisii/7551/2008
95	EPI173178	Kenya	10/17/2008	A/Kisii/7552/2008
96	EPI173179	Kenya	10/17/2008	A/Kisii/7553/2008
97	EPI173180	Kenya	10/17/2008	A/Kisii/7555/2008
98	EPI173181	Kenya	10/21/2008	A/Kisii/7556/2008
99	EPI173182	Kenya	10/23/2008	A/Kisii/7558/2008
100	EPI173183	Kenya	10/28/2008	A/Kisii/7563/2008
101	EPI173184	Kenya	11/4/2008	A/Kisii/7566/2008
102	EPI173185	Kenya	11/5/2008	A/Kisii/7568/2008
103	EPI173186	Kenya	11/5/2008	A/Kisii/7569/2008
104	EPI173193	Kenya	10/3/2008	A/Kisumu/7599/2008
105	EPI173194	Kenya	10/6/2008	A/Kisumu/7600/2008
106	EPI173195	Kenya	10/6/2008	A/Kisumu/7601/2008
107	EPI173196	Kenya	10/6/2008	A/Kisumu/7602/2008
108	EPI173197	Kenya	10/7/2008	A/Kisumu/7603/2008
109	EPI173198	Kenya	10/7/2008	A/Kisumu/7604/2008
110	EPI173199	Kenya	10/8/2008	A/Kisumu/7605/2008
111	EPI173200	Kenya	10/21/2008	A/Kisumu/7609/2008
112	EPI173201	Kenya	10/24/2008	A/Kisumu/7612/2008
113	EPI173202	Kenya	10/28/2008	A/Kisumu/7613/2008
114	EPI173203	Kenya	10/29/2008	A/Kisumu/7614/2008
115	EPI173204	Kenya	11/4/2008	A/Kisumu/7618/2008
116	EPI173205	Kenya	11/4/2008	A/Kisumu/7621/2008
117	EPI173164	Kenya	11/10/2008	A/Kisumu/7627/2008
118	EPI185811	South Korea	12/8/2008	A/Korea/7719/2008
119	EPI185813	South Korea	12/9/2008	A/Korea/7723/2008
120	EPI185815	South Korea	12/13/2008	A/Korea/7858/2008
121	EPI185818	South Korea	12/13/2008	A/Korea/7858/2008
122	EPI185797	Kuwait	1/18/2009	A/Kuwait/494/2009
123	EPI185760	China	12/4/2008	A/Liaoning-Tiedong/14/2008
124	EPI169728	Japan	12/3/2008	A/MIE/34/2008
125	EPI169729	Japan	12/3/2008	A/MIE/36/2008
126	EPI187341	Japan	12/22/2008	A/MIE/43/2008
127	EPI187343	Japan	12/3/2008	A/MIYAGI/36/2008
128	EPI186304	Malaysia	1/6/2009	A/Malaysia/0032/2009
129	EPI173187	Kenya	10/2/2008	A/Malindi/7579/2008
130	EPI173188	Kenya	10/9/2008	A/Malindi/7581/2008
131	EPI173189	Kenya	11/11/2008	A/Malindi/7590/2008
132	EPI185877	USA	1/20/2009	A/Maryland/02/2009
133	EPI175206	USA	12/5/2008	A/Maryland/10/2008
134	EPI185879	USA	1/20/2009	A/Massachusetts/01/2009
135	EPI185881	USA	1/9/2009	A/Massachusetts/02/2009
136	EPI171405	USA	10/29/2008	A/Massachusetts/06/2008
137	EPI172416	USA	10/29/2008	A/Massachusetts/06/2008

138	EPI175211	USA	12/12/2008	A/Massachusetts/13/2008
139	EPI173190	Kenya	11/12/2008	A/Mbagathi/7593/2008
140	EPI185800	Mexico	3/11/2009	A/Mexico/2779/2009
141	EPI175226	USA	12/28/2008	A/Minnesota/36/2008
142	EPI185883	USA	12/23/2008	A/Minnesota/37/2008
143	EPI172444	USA	12/9/2008	A/Montana/02/2008
144	EPI185886	USA	3/3/2009	A/Montana/04/2009
145	EPI185889	USA	1/26/2009	A/Montana/05/2009
146	EPI169730	Japan	11/20/2008	A/NAGANO/1201/2008
147	EPI187353	Japan	12/18/2008	A/NAGOYA/10/2008
148	EPI187357	Japan	2009/00/00	A/NAGOYA/6/2009
149	EPI187359	Japan	3/12/2009	A/NIIGATA/403/2009
150	EPI187679	Japan	5/19/2009	A/NIIGATA/603/2009
151	EPI187680	Japan	6/1/2009	A/NIIGATA/662/2009
152	EPI185891	USA	12/22/2008	A/Nebraska/08/2008
153	EPI185894	USA	4/8/2009	A/Nevada/06/2009
154	EPI185896	USA	2/16/2009	A/New Hampshire/01/2009
155	EPI185899	USA	2/28/2009	A/New Hampshire/04/2009
156	EPI185900	USA	1/27/2009	A/New Mexico/03/2009
157	EPI185904	USA	2/22/2009	A/New York/67/2009
158	EPI185906	USA	12/29/2008	A/North Carolina/08/2008
159	EPI175252	USA	12/15/2008	A/North Dakota/02/2008
160	EPI187682	Japan	5/20/2009	A/OKINAWA/25/2009
161	EPI187684	Japan	5/22/2009	A/OKINAWA/38/2009
162	EPI185908	USA	2/24/2009	A/Oregon/03/2009
163	EPI185910	USA	1/22/2009	A/Pennsylvania/02/2009
164	EPI185913	USA	3/8/2009	A/Pennsylvania/05/2009
165	EPI175262	USA	12/11/2008	A/Pennsylvania/13/2008
166	EPI187703	Australia	4/7/2009	A/Perth/15/2009
167	EPI187702	Australia	4/7/2009	A/Perth/15/2009
168	EPI185159	Australia	4/7/2009	A/Perth/15/2009
169	EPI182941	Australia	4/7/2009	A/Perth/16/2009
170	EPI185157	Australia	4/7/2009	A/Perth/16/2009
171	EPI182939	Philippines	3/5/2009	A/Philippines/16/2009
172	EPI173240	Philippines	11/26/2008	A/Philippines/3803/2008
173	EPI182937	Philippines	3/5/2009	A/Philippines/5/2009
174	EPI185802	Puerto Rico	2/9/2009	A/Puerto Rico/18/2009
175	EPI185709	Canada	1/23/2009	A/Quebec/RV0623/2009
176	EPI185712	Canada	2/11/2009	A/Quebec/RV0899/2009
177	EPI185715	Canada	3/3/2009	A/Quebec/RV1069/2009
178	EPI185718	Canada	3/3/2009	A/Quebec/RV1069/2009
179	EPI187360	Japan	12/19/2008	A/SAGA/204/2008
180	EPI187364	Japan	12/19/2008	A/SAITAMA/47/2008
181	EPI169732	Japan	11/9/2008	A/SAKAI/33/2008
182	EPI187685	Japan	4/28/2009	A/SAKAI/41/2009
183	EPI187366	Japan	12/6/2008	A/SAKAI/53/2008
184	EPI187686	Japan	5/13/2009	A/SAPPORO/112/2009

185	EPI172133	Japan	12/9/2008	A/SHIMANE/106/2008
186	EPI172134	Japan	12/8/2008	A/SHIMANE/107/2008
187	EPI172135	Japan	12/18/2008	A/SHIZUOKA-C/55/2008
188	EPI187374	Japan	12/26/2008	A/SHIZUOKA-C/57/2008
189	EPI187377	Japan	2/20/2009	A/SHIZUOKA/428/2009
190	EPI187378	Japan	2/23/2009	A/SHIZUOKA/448/2009
191	EPI187379	Japan	2/26/2009	A/SHIZUOKA/502/2009
192	EPI187687	Japan	5/23/2009	A/SHIZUOKA/736/2009
193	EPI187688	Japan	6/14/2009	A/SHIZUOKA/791/2009
194	EPI185720	Canada	1/5/2009	A/Saskatchewan/RV0101/2009
195	EPI185763	China	2/22/2009	A/Shanghai-Nanhui/146/2009
196	EPI185766	China	3/12/2009	A/Shanghai-Nanhui/190/2009
197	EPI185769	China	11/4/2008	A/Sichuan-Qingyang/1396/2008
198	EPI175268	China	11/4/2008	A/Sichuan/Qingyang1396/2008
199	EPI190150	Singapore	6/1/2009	A/Singapore/33/2009
200	EPI182943	Singapore	3/27/2009	A/Singapore/39/2009
201	EPI173242	Singapore	11/25/2008	A/Singapore/619/2008
202	EPI185915	USA	12/31/2008	A/South Carolina/07/2008
203	EPI185808	Russia	3/30/2009	A/St. Petersburg/92/2009
204	EPI186310	Australia	1/12/2009	A/Sydney/1/2009
205	EPI186311	Australia	1/20/2009	A/Sydney/3/2009
206	EPI187699	Japan	5/18/2009	A/TOCHIGI/140/2009
207	EPI169744	Japan	11/4/2008	A/TOKUSHIMA/18/2008
208	EPI187394	Japan	12/18/2008	A/TOTTORI/82/2008
209	EPI187694	Taiwan	2/13/2009	A/Taiwan/240/2009
210	EPI169737	Taiwan	10/3/2008	A/Taiwan/540/2008
211	EPI169738	Taiwan	10/3/2008	A/Taiwan/542/2008
212	EPI169739	Taiwan	10/12/2008	A/Taiwan/548/2008
213	EPI169740	Taiwan	10/18/2008	A/Taiwan/549/2008
214	EPI169741	Taiwan	10/31/2008	A/Taiwan/573/2008
215	EPI169742	Taiwan	11/7/2008	A/Taiwan/580/2008
216	EPI169743	Taiwan	11/13/2008	A/Taiwan/599/2008
217	EPI172448	Taiwan	10/25/2008	A/Taiwan/611/2008
218	EPI172450	Taiwan	11/8/2008	A/Taiwan/612/2008
219	EPI187696	Taiwan	5/2/2009	A/Taiwan/712/2009
220	EPI187697	Taiwan	5/2/2009	A/Taiwan/714/2009
221	EPI187698	Taiwan	4/23/2009	A/Taiwan/725/2009
222	EPI185918	USA	1/26/2009	A/Texas/02/2009
223	EPI185920	USA	3/4/2009	A/Texas/03/2009
224	EPI185923	USA	3/18/2009	A/Texas/18/2009
225	EPI175295	USA	12/26/2008	A/Texas/39/2008
226	EPI185820	Thailand	10/3/2008	A/Thailand/860/2008
227	EPI175300	Thailand	11/6/2008	A/Thailand/944/2008
228	EPI175302	Thailand	11/3/2008	A/Thailand/947/2008
229	EPI185823	Thailand	11/12/2008	A/Thailand/981/2008
230	EPI175305	Thailand	11/3/2008	A/Thailand/998/2008
231	EPI185772	China	3/3/2009	A/Tianjin-Hongqiao/141/2009

232	EPI185774	China	12/30/2008	A/Tianjin-Nankai/1211/2008
233	EPI185949	Trinidad and Tobago	2009/00/00	A/Trinidad/2940/2009
234	EPI185925	USA	2/13/2009	A/Vermont/02/2009
235	EPI189220	Australia	6/2/2009	A/Victoria/208/2009
236	EPI189218	Australia	6/2/2009	A/Victoria/209/2009
237	EPI190148	Australia	6/2/2009	A/Victoria/210/2009
238	EPI173254	Australia	1/12/2009	A/Victoria/500/2009
239	EPI176481	Australia	1/25/2009	A/Victoria/502/2009
240	EPI185927	USA	1/5/2009	A/Virginia/02/2009
241	EPI187395	Japan	1/13/2009	A/WAKAYAMA/14/2009
242	EPI185929	USA	1/25/2009	A/Washington/04/2009
243	EPI185931	USA	3/3/2009	A/Washington/05/2009
244	EPI185934	USA	3/30/2009	A/Washington/06/2009
245	EPI172418	USA	12/8/2008	A/Washington/09/2008
246	EPI185937	USA	4/6/2009	A/Washington/15/2009
247	EPI185940	USA	3/16/2009	A/Washington/16/2009
248	EPI185942	USA	1/7/2009	A/Wisconsin/03/2009
249	EPI185944	USA	2/5/2009	A/Wisconsin/05/2009
250	EPI172434	USA	12/3/2008	A/Wisconsin/18/2008
251	EPI175344	USA	12/25/2008	A/Wisconsin/23/2008
252	EPI175346	USA	12/23/2008	A/Wisconsin/24/2008
253	EPI185946	USA	2/2/2009	A/Wyoming/02/2009
254	EPI187396	Japan	11/15/2008	A/YAMAGATA/111/2008
255	EPI187397	Japan	11/16/2008	A/YAMAGATA/112/2008
256	EPI187398	Japan	1/13/2009	A/YAMAGUCHI/15/2009
257	EPI172138	Japan	12/3/2008	A/YAMAGUCHI/30/2008
258	EPI172139	Japan	12/8/2008	A/YAMAGUCHI/35/2008
259	EPI187400	Japan	11/5/2008	A/YAMANASHI/140/2008
260	EPI187402	Japan	3/8/2009	A/YOKOHAMA/107/2009
261	EPI187403	Japan	3/4/2009	A/YOKOHAMA/108/2009
262	EPI187404	Japan	1/27/2009	A/YOKOHAMA/52/2009
263	EPI172142	Japan	12/2/2008	A/YOKOHAMA/97/2008